Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 195 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		VALEO: A Post Authorization Survey, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Natural history/Epidemiology, Treatment				Active				18 and over				Pharmaceutical / Industry				CR003469 NCT00440765


2.		Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Other				TaCyDexVMP7 NCT00652041

Last Modified: 9/10/2008 First Published: 4/23/2005


3.		Phase III Randomized Study of Melphalan and Prednisone With Versus Without Bortezomib in Older Patients With Newly Diagnosed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				65 and over				NCI, Pharmaceutical / Industry				UCLA-0409110-01 JJPRD-26866138-MMY-3002, NCT00111319


4.		MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				EudraCT: 2005-001628-35 EBMT-CLWP: 42206611, NCT00256776


5.		IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 65				Other				BRD 04/11-J NCT00200681


6.		Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				61 to 75				Pharmaceutical / Industry				CR006127 NCT00416208


7.		Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma Age < 60 Years

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				0 to 60				Pharmaceutical / Industry				CR006124 NCT00416273


8.		Efficacy of Bortezomib Consolidation After High-Dose Melphalan With Stem Cell Support in Myeloma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 65				Other				NMSG 15/05 EudraCT No: 2005-002756-18, NCT00417911


9.		GEM05 for Patients With Multiple Myeloma More Than 65 Years Old

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				66 and over				Other				2005-001111-21 NCT00443235


10.		GEM05 for Patients With Multiple Myeloma Under 65 Years

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				65 and under				Other				2005-001110-41 NCT00461747

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute